180 related articles for article (PubMed ID: 31204882)
1. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States.
Gordon S; Lee J; Smith N; Dieterich D
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):251-257. PubMed ID: 31204882
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
Chen P; Jin M; Cao Y; Li H
Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
[TBL] [Abstract][Full Text] [Related]
6. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
Aliment Pharmacol Ther; 2024 May; ():. PubMed ID: 38695095
[TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
8. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.
Curry MP; Flamm SL; Milligan S; Tsai N; Wick N; Younossi Z; Afdhal NH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1239-1248. PubMed ID: 34105360
[No Abstract] [Full Text] [Related]
10. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
Front Public Health; 2021; 9():779215. PubMed ID: 34957030
[No Abstract] [Full Text] [Related]
11. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.
Majethia S; Lee IH; Chastek B; Bunner S; Wolf J; Hsiao A; Mozaffari E
J Manag Care Spec Pharm; 2022 Jan; 28(1):48-57. PubMed ID: 34677088
[No Abstract] [Full Text] [Related]
12. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
Yun H; Zhao G; Sun X; Shi L
BMJ Open; 2020 Aug; 10(8):e035224. PubMed ID: 32819983
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
[TBL] [Abstract][Full Text] [Related]
15. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
Chang KC; Tung SY; Wei KL; Shen CH; Hsieh YY; Chen WM; Chen YH; Chen CH; Yen CW; Xu HW; Tung WL; Hung CH; Lu SN; Chang TS
Sci Rep; 2021 Jun; 11(1):13543. PubMed ID: 34188161
[TBL] [Abstract][Full Text] [Related]
16. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS; Shahoumian TA; Loomis TP; Backus LI
J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Soria A; Fava M; Bernasconi DP; Lapadula G; Colella E; Valsecchi MG; Migliorino GM; D'Ambrosio R; Landonio S; Schiavini M; Spinetti A; Carriero C; Degasperi E; Cologni G; Gatti F; Viganò P; Hasson H; Uberti-Foppa C; Pasulo L; Baiguera C; Rossotti R; Vinci M; Puoti M; Giorgini A; Menzaghi B; Lombardi A; Pan A; Aghemo A; Grossi PA; Boldizzoni R; Colombo S; Viganò M; Rumi MG; Del Poggio P; Valenti L; Giglio O; De Bona A; d'Arminio Monforte A; Colombo A; Spinelli O; Pigozzi MG; Molteni C; Bonfanti P; Terreni N; Perini P; Capretti A; Bella D; Liani C; Polo S; Aimo G; Pagnucco L; Bhoori S; Centenaro R; Graffeo M; Ciaccio A; Dionigi E; Lazzaroni S; Carderi I; Di Marco M; Rizzardini G; Noventa F; Lampertico P; Fagiuoli S
Liver Int; 2020 Apr; 40(4):769-777. PubMed ID: 31970845
[TBL] [Abstract][Full Text] [Related]
19. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P; Tiong KLA; Neo JE; Mohan BP; Wijarnpreecha K; Tam YCS; Coppola N; Preda CM; Wong YJ
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515176
[TBL] [Abstract][Full Text] [Related]
20. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]